Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis

Critical Care Medicine

Volumn 28, Issue 9 SUPPL., 2000, Pages

  Abraham, E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Coagulation; Endothelium; Sepsis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; INTERLEUKIN 6; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

AMINO ACID SEQUENCE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEPSIS;

EID: 0033816376     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200009001-00007     Document Type: Review

References (14)

1. The haematological manifestations of sepsis
2. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia
3. Tissue factor in health and disease
4. Tissue factor pathway inhibitor: Potential therapeutic applications
5. Disseminated intravascular coagulation: Pathophysiology, diagnosis, and treatment
6. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells
7. Regulation of coagulation by a multivalent Kunitz-type inhibitor
8. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
9. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
10. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
11. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor inhibitor
12. The systemic inflammatory response: Perspective of human endotoxemia
13. Cofactors V and VIII after endotoxin administration to human volunteers
14. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo